In this video, moderator Dr. Agarwal discusses the VISION trial with Dr. Scott Tagawa, a co-author on the New England Journal Medicine Paper on the primary results of the VISION Trial. They continue their discussion covering how lutetium-177 PSMA-617 will be incorporated into treating patients with metastatic CRPC. To end their conversation, Dr. Tagawa talks about how this agent and similar agents or approaches will be moving to other earlier states of prostate cancer.The Moderator: Neeraj Agarwal, MD, is an internationally recognized physician-scientist in the field of genitourinary cancers and is a Professor of medicine and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI.The Panel of Experts: Dr. Jeremie Calais: Director of the UCLA Clinical theranostic Program and an Associate Professor at the Ahmanson Translational Theranostics Division of the Department of Molecular and Medical Pharmacology at UCLA. Dr. Calais received his MD degree from the University of Paris, France. He is a nuclear medicine physician specializing in cancer imaging and theranostics.Scott T. Tagawa, MD, MS, FACP: Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at New York-Presbyterian – Weill Cornell Medical Center. As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer.Jonathan Tward, MD, Ph.D.: A tenured Professor in the Department of Radiation Oncology at the University of Utah who holds the Rudolph P. and Edna S. Reese Endowed Research Professorship. He is recognized as a major authority and key-opinion leader in treating prostate, bladder, and penile cancers. Dr. Tward is the leader of the Huntsman Cancer Institute's (HCI) Genitourinary Cancers Center (GUCC).